ConductScience.org, home

Paper42872079PubMed

Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway.

Cui Y and 9 others. J Geriatr Cardiol, 2026.

Cite this record

ConductScience Library. Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway. Papers, record 42872079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872079

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway.
Journal
J Geriatr Cardiol
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-15

Source PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cui YYan
2Li WPWei-Peng
3Yu YYue
4Lu PPeng
5Li JWJia-Wen
6Zhao CCan
7Xu JSJin-Shui
8Shen ZKZheng-Kai
9Lu XXiang
10Gao WWei

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141015484Sex-specific protective effects of angiotensin II type 1 receptor knockdown on disuse muscle atrophy in the rat soleus muscle.J Appl Physiol (1985)2025https://conductscience.org/library/papers/41015484PubMed
225080489Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase.Am J Physiol Cell Physiol2014https://conductscience.org/library/papers/25080489PubMed
339996717Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II.Cells2025https://conductscience.org/library/papers/39996717PubMed
422071238Azilsartan medoxomil: a new Angiotensin receptor blocker.Clin Ther2011https://conductscience.org/library/papers/22071238PubMed
523034963Malnutrition self-screening by using MUST in hospital outpatients: validity, reliability, and ease of use.Am J Clin Nutr2012https://conductscience.org/library/papers/23034963PubMed
640151633Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision).J Geriatr Cardiol2025https://conductscience.org/library/papers/40151633PubMed
739384003Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K/AKT/FoxO3a signaling pathway.Cell Signal2024https://conductscience.org/library/papers/39384003PubMed
826571361Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression.Sci Rep2015https://conductscience.org/library/papers/26571361PubMed
932234320Branched-chain amino acid supplementation ameliorates angiotensin II-induced skeletal muscle atrophy.Life Sci2020https://conductscience.org/library/papers/32234320PubMed
1016399230Angiotensin II directly inhibits protein synthesis in murine myotubes.Cancer Lett2006https://conductscience.org/library/papers/16399230PubMed
1142119273Dysregulation of the ubiquitin-proteasome system in aging skeletal muscle.Biomed Pharmacother2026https://conductscience.org/library/papers/42119273PubMed
1231420755Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome.Cardiovasc Drugs Ther2019https://conductscience.org/library/papers/31420755PubMed
1332033882Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment.J Am Med Dir Assoc2020https://conductscience.org/library/papers/32033882PubMed
1438583268Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies.Mol Aspects Med2024https://conductscience.org/library/papers/38583268PubMed
1534389456Skeletal muscle atrophy: From mechanisms to treatments.Pharmacol Res2021https://conductscience.org/library/papers/34389456PubMed
1637062187Azilsartan Ameliorates Skeletal Muscle Wasting in High Fat Diet (HFD)-induced Sarcopenic Obesity in Rats via Activating Akt Signalling Pathway.Arch Gerontol Geriatr2023https://conductscience.org/library/papers/37062187PubMed
1734343333Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway.J Pharm Pharmacol2021https://conductscience.org/library/papers/34343333PubMed
1835988789Effect of losartan treatment on Smad signaling and recovery from hindlimb unloading-induced soleus muscle atrophy in female rats.Eur J Pharmacol2022https://conductscience.org/library/papers/35988789PubMed
1921562229Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.Sci Transl Med2011https://conductscience.org/library/papers/21562229PubMed
2025580531Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle.Exp Physiol2015https://conductscience.org/library/papers/25580531PubMed

See all 32 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42872079

GET https://conductscience.org/api/papers/v1/42872079/references?page=2